JP7506607B2 - ＴｆＲに結合するバイスペシフィック抗体 - Google Patents

ＴｆＲに結合するバイスペシフィック抗体 Download PDF

Info

Publication number
JP7506607B2
JP7506607B2 JP2020562545A JP2020562545A JP7506607B2 JP 7506607 B2 JP7506607 B2 JP 7506607B2 JP 2020562545 A JP2020562545 A JP 2020562545A JP 2020562545 A JP2020562545 A JP 2020562545A JP 7506607 B2 JP7506607 B2 JP 7506607B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
tfr
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020562545A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020138487A1 (ja
JPWO2020138487A5 (https=
Inventor
圭祐 三田村
了輔 中野
正之 甲斐
信明 高橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of JPWO2020138487A1 publication Critical patent/JPWO2020138487A1/ja
Publication of JPWO2020138487A5 publication Critical patent/JPWO2020138487A5/ja
Priority to JP2024096802A priority Critical patent/JP2024119984A/ja
Application granted granted Critical
Publication of JP7506607B2 publication Critical patent/JP7506607B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
JP2020562545A 2018-12-28 2019-12-27 ＴｆＲに結合するバイスペシフィック抗体 Active JP7506607B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024096802A JP2024119984A (ja) 2018-12-28 2024-06-14 ＴｆＲに結合するバイスペシフィック抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018248334 2018-12-28
JP2018248334 2018-12-28
PCT/JP2019/051594 WO2020138487A1 (ja) 2018-12-28 2019-12-27 ＴｆＲに結合するバイスペシフィック抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024096802A Division JP2024119984A (ja) 2018-12-28 2024-06-14 ＴｆＲに結合するバイスペシフィック抗体

Publications (3)

Publication Number Publication Date
JPWO2020138487A1 JPWO2020138487A1 (ja) 2021-11-11
JPWO2020138487A5 JPWO2020138487A5 (https=) 2023-08-28
JP7506607B2 true JP7506607B2 (ja) 2024-06-26

Family

ID=71125764

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562545A Active JP7506607B2 (ja) 2018-12-28 2019-12-27 ＴｆＲに結合するバイスペシフィック抗体
JP2024096802A Pending JP2024119984A (ja) 2018-12-28 2024-06-14 ＴｆＲに結合するバイスペシフィック抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024096802A Pending JP2024119984A (ja) 2018-12-28 2024-06-14 ＴｆＲに結合するバイスペシフィック抗体

Country Status (13)

Country Link
US (2) US12258413B2 (https=)
EP (1) EP3903816A4 (https=)
JP (2) JP7506607B2 (https=)
KR (1) KR20210108961A (https=)
CN (1) CN113226371B (https=)
AU (1) AU2019413278B2 (https=)
BR (1) BR112021012569A2 (https=)
CA (1) CA3125316A1 (https=)
MX (1) MX2021007797A (https=)
MY (1) MY210422A (https=)
SG (1) SG11202106990PA (https=)
TW (2) TWI873112B (https=)
WO (1) WO2020138487A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
EP4434548A1 (en) 2021-11-15 2024-09-25 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
EP4688846A1 (en) * 2023-03-24 2026-02-11 BioArctic AB Antibody binding to the protease-like domain of the human transferrin receptor htfr1
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025090898A1 (en) * 2023-10-26 2025-05-01 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof cross reference to related applications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131239A1 (ja) 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
JP2014500886A (ja) 2010-11-30 2014-01-16 ジェネンテック， インコーポレイテッド 低親和性血液脳関門受容体抗体及びその使用
JP2015523336A (ja) 2012-05-21 2015-08-13 ジェネンテック， インコーポレイテッド 血液脳関門輸送の安全性を改善するための方法
JP2016526878A (ja) 2013-05-20 2016-09-08 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US570561A (en) 1896-11-03 S peters co
US2808035A (en) 1953-04-23 1957-10-01 Riley Stoker Corp Burning wet materials
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
JPS60221091A (ja) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2564268B2 (ja) 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JP3131322B2 (ja) 1991-12-17 2001-01-31 協和醗酵工業株式会社 新規α２→３シアリルトランスフェラーゼ
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
SG49117A1 (en) 1993-03-29 1998-05-18 Kyowa Hakko Kogyo Kk Alfa -1, 3-fucosyltransferase
US5705614A (en) 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
EP2990420B1 (en) * 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
WO2003033538A1 (en) 2001-10-15 2003-04-24 Kirin Beer Kabushiki Kaisha Anti-hla-dr antibody
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
KR20120024763A (ko) * 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
BRPI1010759B1 (pt) 2009-06-11 2019-07-16 Inter-University Research Institute Corporation Research Organization Of Information And Systems Método para produzir uma proteína de interesse ou para obter uma suspensão de células de mamíferos capaz de produzir uma proteína de interesse, bem como vetor de expressão de proteína
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CN105968209B (zh) 2011-04-19 2021-08-03 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
MX361875B (es) 2012-03-14 2018-12-18 Regeneron Pharma Moléculas de unión de antígeno multiespecifícas y usos de las mismas.
CN104211814A (zh) 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
TWI853985B (zh) * 2013-12-04 2024-09-01 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
SG11201608253XA (en) * 2014-04-04 2016-10-28 Kyowa Hakko Kirin Co Ltd Anti-death receptor 3 (dr3) antagonistic antibodies with reduced agonistic activity
EP3221362B1 (en) * 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
EP3221361B1 (en) * 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
SG11201705632UA (en) * 2015-01-08 2017-08-30 Kyowa Hakko Kirin Co Ltd Bispecific antibody binding to trailr2 and psma
MX391086B (es) * 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
CA2992262A1 (en) * 2015-07-15 2017-01-19 Kyowa Hakko Kirin Co., Ltd. Antibody which specifically binds to human crth2
KR20190005944A (ko) 2016-05-09 2019-01-16 애넥슨, 인코포레이티드 척수성 근위축 치료용 조성물 및 방법
KR102156626B1 (ko) 2018-07-16 2020-09-17 주식회사 셀바스에이아이 운동 처방 정보를 제공하는 서버 및 컴퓨터 프로그램

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131239A1 (ja) 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
JP2014500886A (ja) 2010-11-30 2014-01-16 ジェネンテック， インコーポレイテッド 低親和性血液脳関門受容体抗体及びその使用
JP2015523336A (ja) 2012-05-21 2015-08-13 ジェネンテック， インコーポレイテッド 血液脳関門輸送の安全性を改善するための方法
JP2016526878A (ja) 2013-05-20 2016-09-08 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法

Also Published As

Publication number Publication date
SG11202106990PA (en) 2021-07-29
US20220017635A1 (en) 2022-01-20
BR112021012569A2 (pt) 2021-09-14
JPWO2020138487A1 (ja) 2021-11-11
AU2019413278B2 (en) 2026-04-09
AU2019413278A1 (en) 2021-07-15
WO2020138487A1 (ja) 2020-07-02
KR20210108961A (ko) 2021-09-03
US20250250352A1 (en) 2025-08-07
NZ777568A (en) 2025-05-02
TW202517296A (zh) 2025-05-01
EP3903816A1 (en) 2021-11-03
CA3125316A1 (en) 2020-07-02
MX2021007797A (es) 2021-10-26
JP2024119984A (ja) 2024-09-03
EP3903816A4 (en) 2022-09-07
US12258413B2 (en) 2025-03-25
CN113226371B (zh) 2025-05-30
TWI907249B (zh) 2025-12-01
TWI873112B (zh) 2025-02-21
CN113226371A (zh) 2021-08-06
MY210422A (en) 2025-09-22
TW202039581A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
US20240059788A1 (en) BISPECIFIC ANTIBODY WHICH BINDS TO CD40 AND EpCAM
KR101846590B1 (ko) 항 ｔｉｍ-3 항체
JP7506607B2 (ja) ＴｆＲに結合するバイスペシフィック抗体
US20220259328A1 (en) Bispecific antibody binding to cd40 and fap
US20180016346A1 (en) Bispecific antibody binding to trailr2 and psma
JP7502281B2 (ja) Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体
US20250092148A1 (en) Bispecific antibody that binds to cd116 and cd131
RU2810756C2 (ru) Биспецифические антитела, связывающиеся с tfr
WO2021261597A1 (ja) ＧＰＣ３とＴｆＲに結合するバイスペシフィック抗体
HK40062464A (en) Bispecific antibody binding to tfr
HK40038050A (en) Bispecific antibody which binds to cd40 and epcam

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240614